{"name":"Arrevus Inc.","slug":"arrevus-inc","ticker":"","exchange":"","domain":"","description":"Arrevus Inc. is a biotechnology company focused on developing innovative treatments for infectious diseases. The company has a pipeline of four drug candidates, with two in Phase 2 trials and one discontinued project.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARV-1801","genericName":"ARV-1801","slug":"arv-1801","indication":"Hematologic malignancies (Phase 2 development)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ceftazidime or meropenem","genericName":"Ceftazidime or meropenem","slug":"ceftazidime-or-meropenem","indication":"Nosocomial pneumonia","status":"phase_2"}]}],"pipeline":[{"name":"ARV-1801","genericName":"ARV-1801","slug":"arv-1801","phase":"phase_2","mechanism":"ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer.","indications":["Hematologic malignancies (Phase 2 development)"],"catalyst":""},{"name":"Ceftazidime or meropenem","genericName":"Ceftazidime or meropenem","slug":"ceftazidime-or-meropenem","phase":"phase_2","mechanism":"Ceftazidime and meropenem are broad-spectrum cephalosporin antibiotics that inhibit bacterial cell wall synthesis.","indications":["Nosocomial pneumonia","Complicated urinary tract infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPM0lERldrbUY4VXU4eHhSaU82NlNRU1FJelZFZXVnbHpjdTYwZEZSWUx0ODZHY0lhWW1JRnpBYk9JTFA3UGlSRDFIeUdZUEFCTWRURnBOYTZ2SXNINS1IUkw0N0ZPSDFOYktkczFWdzE1ZDY5Mk0yU2hHMXk0Z3hWdmZTcTJlOURkbFNGenhyYjI0NGg3TG1SYWtOTjhvNTFVamE1b21oQnJ1eWd5WkZWeFJzRU5lUlBvVVFmRko4QXhjMjd0aVJFZEhlQ1dkYmhoRDFlYzcxYXMwSWhCejhNZDdNX1FjVDRrOHc?oc=5","date":"2021-11-01","type":"pipeline","source":"GlobeNewswire","summary":"Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline - GlobeNewswire","headline":"Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}